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Tumor microenvironments, the immune system and cancer
survival
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Abstract
The study of cancer immunology has recently been reinvigorated by the application of new
research tools and technologies, as well as by refined bioinformatics methods for interpretation
of complex datasets. Recent microarray analyses of lymphomas suggest that the prognosis of
cancer patients is related to an interplay between cancer cells and their microenvironment,
including the immune response. 
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That the immune system plays an important role in the regu-
lation and outcome of cancer has been an intriguing concept
for almost a century. As discussed by Dunn et al. [1,2],
although many observations supported the notion that the
ability of cancer to escape the tumor-controlling features of
the immune system can be considered a hallmark of cancer,
for many years the scientific evidence was conflicting and
consensus did not emerge. More recently, however,
advances in approaches that perturb specific gene functions
in well-defined mouse models of cancer have convincingly
demonstrated the importance of the interface between
cancer and the immune system [2]. Together with a large
body of evidence from human cancers, these advances have
generated renewed interest in understanding the role of the
host inflammatory response in cancer and in using that
knowledge towards the development of new approaches to
cancer immunotherapy and vaccination [3-10]. The recently
reported results of two groups [11,12] give new insights into
the factors that affect survival of patients with lymphomas,
including the importance of the immune system.
Initially, the study of cancer immunobiology was framed
within the context of ‘immunosurveillance’ [13], with focus
on the role of the immune system in recognizing and inhibit-
ing cancer growth. More recently, it has been recognized that
the interrelationship between cancer and the immune
system is highly complex and can take very different paths -
for instance, from suppression of tumor growth by the
immune system or enhancement of tumor progression
through the selection of cells so that they lack signals recog-
nized by the immune system. Given this complex biology, it
has been suggested that the term immunosurveillance [13]
be replaced with the more comprehensive term ‘immuno-
editing’, encompassing three phases: elimination, equilib-
rium, and escape [1] (Figure 1). In the elimination phase,
which is perhaps the most similar to the original concept of
immunosurveillance, the immune system attempts to eradi-
cate the cancer. If this process is unsuccessful, the cancer
and the immune system achieve a balance, referred to here
as equilibrium, in which the immune system is able to
contain but not eliminate the cancer. During the equilibrium
phase the cancer is under constant pressure from the
immune system but can also undergo genetic changes that
can lead to increased immune resistance. If, following many
rounds of selection and genetic change, the cancer cells
become resistant to immune attack, the escape phase com-
mences, in which the cancer cells are now free to progress,
even in the presence of an intact immune system.
Microarrays and cancer immunology
Out of this background have emerged new technological
advances, including microarrays, which provide the oppor-
tunity comprehensively to assess gene expression in tumors,their component cells, and their microenvironment. Among
the important advances that have derived from these tech-
nologies is the molecular classification of tumors on the basis
of only their gene-expression patterns, resulting in the identi-
fication of ‘diseases within diseases’, different subtypes of
known cancers that differ in both gene expression patterns
and prognosis (survival time or likelihood of relapse) [14-24].
Until recently, microarray-based correlations between gene
expression and clinical outcome have been attributed
directly to malignant cells within tumors. 
The recently published results of two studies [11,12] not only
give a new opportunity to probe the biology of cancer
immunology more comprehensively but also emphasize the
general importance of tumor-infiltrating immune cells in
disease progression. For the diseases that are the subject of
these studies, namely follicular lymphoma and diffuse B-cell
lymphoma, patient survival is very heterogeneous, and it is
important to generate improved diagnostics for assessing
predicted disease progression in individual patients. Attain-
ment of this goal will help physicians to decide the best
course of treatment and will also increase our understanding
of how the underlying biology correlates with survival,
thereby suggesting potential new avenues for intervention. 
In the study of Dave and colleagues [11], biopsy samples
from untreated lymphoma patients were examined by gene-
expression profiling on microarrays. Informatics methods
were used to identify ‘signatures’ - expression patterns that
correlated with disease outcome - which were then validated
in independent samples. Among the gene-expression signa-
tures were two, named immune-response 1 (ir1) and
immune-response 2 (ir2), that together could be used to
make the best predictive model of patient survival. The sig-
natures allowed patient outcome to be segmented into quar-
tiles, with patients in the best prognosis quartile (which had
ir1 but not ir2) having median survival times of more than 13
years, and those in the worst prognosis quartile (which had
ir2 but not ir1) having an average survival of less than 4
years. Among the ir1 genes (associated with favorable sur-
vival) were T-cell markers such as CD7 and CD8B1 as well as
the macrophage markers ACTN1 and TNFSF13B. Impor-
tantly, the gene-expression pattern predicting good progno-
sis is not simply a generalized T-cell response, as other T-cell
markers such as CD2 and CD4 were not correlated with sur-
vival. The presence of CD8+ (cytotoxic) T-cells is an impor-
tant feature, as these probably have a direct tumor-killing
role [1]. In the ir2 set (associated with poor prognosis) were
both macrophage markers (distinct from those in ir1) and
dendritic-cell markers. Following sorting of malignant from
non-malignant cells using the CD19 marker, which malig-
nant cells lack, it was established that the ir1 and ir2 signa-
tures were expressed in the non-malignant cells. Therefore,
in this study, patient outcome was most directly associated
with the type of immune response, not the expression profile
of the cancer cells themselves.
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Figure 1
The three Es of cancer immunoediting: elimination, equilibrium, and escape. (a) After transformation of cells in a normal layer (diamond-shaped cells) into
cancerous cells (with irregular shapes), attack by various different cell types of the immune system (indicated by round cells) may lead to elimination of the
cancerous cells. (b) If elimination is unsuccessful, the immune system and the cancer can reach an equilibrium in which immune cells keep the cancer in
check but cannot remove it completely. During the elimination phase, there is selection on the cancer cells, whose genomes are also unstable. This can
lead to escape (c), in which mutated cancer cells become able to inhibit the immune system. The cancer can then grow unchecked. Figure modified from
[2]. CD4+, CD8+, CD4+CD25+ Treg, γδ and NKT cells are all types of T cell; Mφ cells are macrophages and NK cells are natural killer cells.
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(a) Elimination (b) Equilibrium (c) EscapeA distinctly different result was seen in the recent study by
Monti and colleagues [12] of the most common lymphoma in
adults, diffuse large B-cell lymphoma (DLBCL). This lym-
phoma has previously been the subject of a series of gene-
expression profiling studies, including now-classic studies
demonstrating the ‘disease within disease’ concept and cor-
relating gene-expression signatures with cells of origin and
patient survival [12,25-27]. The recent study [12] used
whole-genome arrays, multiple clustering algorithms and
knowledge of previously identified genetic aberrations to
identify three distinct groups of DLBCL, including an ‘oxida-
tive phosphorylation’ group (which showed elevated expres-
sion of oxidative phosphorylation, mitochondrial, and
electron transport chain genes) and a group called
‘BCR/proliferation’ (which showed elevated expression of
genes encoding cell-cycle regulators, DNA-repair genes, the
B-cell receptor signaling cascade, and B-cell associated tran-
scription factors). The third group was termed ‘host
response’ (HR) and had expression of a suite of immune
components such as T/NK-cell receptor and activation path-
ways, the complement cascade, macrophage and dendritic-
cell markers and inflammatory mediators. Among the
immune components in the HR group were markers of
CD2+/CD3+ tumor-infiltrating lymphocytes. Clearly, the HR
signature is very consistent with an active inflammatory
response. But, patient survival was not improved in the HR
group: this may reflect a different immunoediting result
compared with the results observed for follicular lymphoma,
perhaps for example a less effective elimination phase. Alter-
natively, this may reflect an overall balance in a series of
complex factors that could reflect the immunoediting
process. For example, tumors in the HR group had less pro-
nounced genetic abnormalities and also occurred more fre-
quently in younger patients. Thus, it is possible to discern
the features of the host, the cancer, and the immune
response that impact on the different biological features of
these cancers and ultimately on patient outcome.
The importance of tumor microenvironment
The combined use of new technologies, such as monoclonal
antibodies that perturb specific functions, together with
improved mouse model systems that have specifically
defined genetic modifications, have provided new insights
into the cancer surveillance process, thereby leading to a
more refined concept of immunoediting. The studies of Dave
et al. [11] and Monti et al. [12] now give impetus to this rein-
vigorated approach. These studies highlight the importance
of studying the genetics and phenotypes not only of cancer
cells but also of the surrounding microenvironment. The
immune system has long been known to be an important
part of this microenvironment, although our biological
knowledge of specific mechanisms remains incomplete. 
The application of microarrays to follicular lymphoma and
DLBCL [11,12] presents a remarkable new opportunity to
gain a wider perspective of the biology of cancer and its
microenvironment. It will be increasingly important to inte-
grate microarray technology with immunohistochemistry,
such that not only can the types of T-cells present be discerned
but also their localization with respect to cancer cells
[12,28,29]. Moreover, through the improved definition of the
immune response to tumors, new avenues will open for learn-
ing how to harness the immune response more effectively to
improve cancer outcomes. Excitingly, it is clear that this
opportunity includes many other and perhaps all cancers, as
tumor-infiltrating lymphocytes are associated with a diversity
of tumors [2,10,30,31]. Thus, through the application of tech-
nologies such as microarrays, together with very careful anno-
tation of tumors and patient information, it is hoped that new
strategies will emerge for monitoring and controlling the
development of new tumors and for more effective targeting of
the tumors that have already formed.
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